Discussion
Fasenra (benralizumab) may provide fast and meaningful benefits for people with severe eosinophilic granulomatosis with polyangiitis (EGPA) who test negative for self-reactive antibodies called ANCAs, according to a small real-world case series. In all three reported cases, AstraZeneca’s treatment resulted in a fast and complete depletion of eosinophils,…